Financial Performance - The company reported a net profit of 122 million yuan for the first half of 2025, a decrease of 29.27% year-on-year [1] - Total operating revenue for the same period was 507 million yuan, down 14.08% compared to the previous year [1] - The gross margin was 64.7%, a decline of 3.4% year-on-year, while the net profit margin fell to 23.86%, down 17.75% [1] - The company’s total expenses (selling, administrative, and financial) amounted to 102 million yuan, representing 20.1% of revenue, an increase of 23.58% year-on-year [1] Cash Flow and Assets - The company reported cash flow from operations of 0.27 yuan per share, an increase of 35.3% year-on-year [1] - The net asset value per share increased to 4.8 yuan, up 10.41% year-on-year [1] - The company’s cash assets are considered very healthy, with cash and cash equivalents reported at 1.511 billion yuan, a 13.35% increase [3] Business Development - The company has launched its mid-speed chemiluminescence immunoassay analyzers, eCL8600 and eCL8800, which received CE certification in April 2025, enhancing its international market competitiveness [3][4] - The mid-speed products are designed to meet the needs of laboratories and public hospitals in certain overseas markets, complementing existing small luminescence instruments [3] - The company is also advancing the registration of mid-speed luminescence products in the domestic market, targeting secondary hospitals to serve basic healthcare needs [4] Product Innovation - The company’s carbon dioxide laser treatment machine has obtained domestic Class III medical device registration, capable of treating various skin conditions and reducing fine wrinkles [5] - Future plans include continued investment in research and development to expand the aesthetic medical product line, aligning with consumer demand [5]